AstraZeneca, Abbott partner on combo drug

AstraZeneca and Abbott Laboratories said they plan to co-develop and market a combination cholesterol drug. The pill would combine AZ’s cholesterol-lowering drug Crestor with Abbott’s ABT-335, currently in Phase III clinical trials for raising HDL or "good" cholesterol and reducing triglycerides. The companies say they also will evaluate a combination drug based on Crestor and Abbott’s TriCor, which is approved for lowering triglycerides. TriCor is licensed to Abbott for US marketing by Solvay. ABT-335 is a next-generation version of TriCor. Final selection between the two drugs will be made based upon data generated from initial studies, the companies said, with FDA filing expected in 2009.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions